Open me in the App!
Chapters
Hello and Welcome Clinical Statement
Chapter 1:
Epidemiology
Chapter 2:
Diagnostic Tests for Latent TB Infection (LTBI)
Tuberculin Skin Test
Criteria for a Positive Tuberculin Test by Risk Group
Two Step Testing and the Booster Reaction
Anergy Testing
Interferon-γ Release Assays (IGRAs)
Targeted Testing and Diagnostic Tests for LTBI
Medical Evaluation After Testing for LTBI
Reporting of Pediatric Positive Tests for LTBI
Chapter 3:
Treatment of Latent TB Infection (LTBI)
Treatment Regimens
Monitoring of Patients on Treatment for LTBI
Contacts of MDR TB Cases
Chapter 4:
Laboratory Diagnosis of Active Tuberculosis
Considerations
Selected Diagnostic Test Characteristics
Laboratory Diagnosis of Pulmonary Tuberculosis
Laboratory Diagnosis of Extrapulmonary Tuberculosis
Rapid Molecular Drug Susceptibility Tests (DST)
Chapter 5:
Treatment of Current (Active) Disease Therapy
Considerations
Standard Therapy for Current (Active) Disease
Special Clinical Situations
Drug Resistance
Monitoring Patients on Therapy for Response and Adverse Events
TB and HIV
Immune Reconstitution Inflammatory Syndrome
Treatment of Extrapulmonary TB
Adjunctive Use of Corticosteroid Therapy
Chapter 6:
Pregnancy and TB
Treatment for LTBI and Risk Factors
Treatment of Active TB in Pregnancy
Chapter 7:
Childhood Tuberculosis
Management Considerations
Chapter 8:
Tuberculosis and Long Term Care Facilities
Chapter 9:
BCG Vaccination
Chapter 10:
TB Infection Control Hospital Isolation Procedures
Administrative Controls
Surveillance for Health Care Workers
Environmental Controls
Personal Respiratory Protection
Chapter 11:
Community Tuberculosis Control
TB Surveillance in Georgia
How to Report TB as a Notifiable Disease
TB Case Definitions for Public Health Surveillance
Role of the Health Department
Hospital Discharge Planning for Patients with Suspected or Proven TB
Interjurisdictional TB Notification (IJN)
CureTB Program (International Linkage to TB Care)
Chapter 12:
Alternative Housing Program for Homeless TB Patients in Georgia
Chapter 13:
Georgia Department of Public Health (DPH) Community Guidelines for Respiratory
Figure 1:
Factors to be Considered
References:
References
Appendix:
Appendix District TB Coordinators (by District)
Abbreviations:
Abbreviations
Acknowledgements:
Acknowledgements
For More Information:
For More Information
About Us
Quote
Tables
Table 1: Interpretation Criteria for the QuantiFERON-TB Gold Plus Test
Table 2: Interpretation Criteria for the T-SPOT.TB Test
Table 3: High Prevalence and High Risk Groups
Table 4: Recommendations for Regimens to Treat Latent Tuberculosis Infection
Table 5: Dosages for Recommended LTBI Treatment Regimens
Table 6: LTBI Treatment Drug Adverse Reactions
Table 7: Recommended Regimens for Treatment of Adults and Children with Drug Susceptible TB (Pulmonary TB)
Table 8: First-line TB Drugs: Dosing for Adults (ages 16 and over) Directly Observed Therapy (DOT) is mandatory
Table 9: Pediatric Dosage Isoniazid in Children (Birth to 15 Years)
Table 10: Antituberculosis Antibiotics in Adult Patients with Renal Impairment
Table 11: Antituberculosis Medications which may be used for patients who have contraindications to or intolerance
Table 12: Clinical Situations for which Standard Therapy cannot be given or is not well-tolerated
Table 13: When to Start HIV Therapy
Table 14: What to Start: Choice of TB Therapy and Antiretroviral Therapy (ART) When Treating Co-infected Patients
Table 15: Summary of Recommendations for Treatment of Active TB Disease in Persons with HIV
Table 16: Guidelines for Treatment of Extrapulmonary Tuberculosis
Table 17: Use of Anti-TB Medications in Special Situations: Pregnancy, Tuberculosis Meningitis and Renal Failure
Table 18: Dosage Adjustments for ART and Rifamycins when Used in Combination
Table 19: Grady Hospital TB Isolation Policy